Announcements Trials
Browse Landscape Eligibility

Clinical Trials

1 trials
RecentStart dateEnrollment
PFS × Clear all

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 12991Neoplasms 10383Carcinoma, Non-Small-Cell Lung 6796Prostatic Neoplasms 6198Colorectal Neoplasms 5864Lung Neoplasms 5042Multiple Myeloma 3542Pancreatic Neoplasms 3512Neoplasm Metastasis 3480Leukemia, Myeloid, Acute 3469Carcinoma, Hepatocellular 3232Ovarian Neoplasms 3138Melanoma 3120Stomach Neoplasms 3020Lymphoma 2970Head and Neck Neoplasms 2575Recurrence 2528Precursor Cell Lymphoblastic Leukemia-Lymphoma 2485Leukemia 2353Colonic Neoplasms 2317Brain Neoplasms 2293Lymphoma, Non-Hodgkin 2257Rectal Neoplasms 2173Uterine Cervical Neoplasms 2164Glioblastoma 1993Leukemia, Lymphocytic, Chronic, B-Cell 1985Carcinoma, Renal Cell 1897Squamous Cell Carcinoma of Head and Neck 1857Lymphoma, Follicular 1829Esophageal Neoplasms 1786

Interventions

Bevacizumab 1Afatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements
NCT05267288 2023-03-29

Phase II Study of Afatinib Plus Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon G719X, S768I, and L861Q Mutation Metastatic Non-Small Cell Lung Cancer

Qingdao Central Hospital

Phase 2 Unknown
30 enrolled

PFS

Data powered by HemOnc (CC BY 4.0) Colophon âš¡